FDA Announces New Policy to Expedite Treatments for Very Rare Diseases
The Food and Drug Administration (FDA) has announced a new policy aimed at expediting the approval process for cutting-edge treatments for very rare diseases. This guidance allows the agency to approve new treatments based on evidence of a "plausible mechanism" for how the treatment would function.
Policy Details
The policy seeks to accelerate the use of state-of-the-art technologies, such as gene-editing, to develop treatments tailored for individual patients.
It specifically addresses diseases so rare that conducting traditional clinical studies is challenging or impossible.
This approach applies when there is a plausible expectation that the treatment will work, for instance, a clear understanding of the genetic defect causing a disorder and how the treatment would address it.
Background and Rationale
Health and Human Services Secretary Robert F. Kennedy Jr. stated the policy aims to overcome historical challenges in developing treatments for rare diseases, emphasizing the shift toward individualized medicine. FDA Commissioner Marty Makary noted the significant progress in the FDA's approach to rare diseases.
The policy was partly prompted by the case of a Pennsylvania infant treated at the Children's Hospital of Philadelphia (CHOP). Doctors at CHOP successfully treated the baby, who had a rare genetic liver disorder, by creating a gene-editing treatment specific to the child's genetic defect. This approach could be adapted for similar conditions. Dr. Kiran Musunuru, involved in developing the treatment, indicated its potential to treat many patients.
Impact and Expert Reaction
This new policy could make it more feasible and affordable to develop gene-editing treatments for a wide range of rare genetic conditions. While scientists have been developing gene-editing therapies like CRISPR for disorders such as sickle cell disease and other conditions including cancer and genetic blindness, pharmaceutical companies often lack economic incentive for extremely rare disorders.
Fyodor Urnov of the University of California, Berkeley, praised the guidance, stating it would allow for faster and more affordable treatment for children.
Dr. Tracy Beth Høeg, director of the FDA's Center for Drug Evaluation and Research, described the announcement as exciting for patients with very rare diseases.
However, some experts expressed concerns about the policy's potential scope. Rachel Sachs, a law professor at Washington University in St. Louis, raised questions about the possibility of expanding the "plausible mechanism" pathway to common diseases where traditional trials are feasible and might still be necessary.